Navigation Links
Resverlogix Updates Shareholders on Accelerated Clinical Trial Plan
Date:10/16/2009

se and other vascular disorders. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as defined under applicable Canadian securities legislation, including our vision to be a leader in the research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular disease including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases. These forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those associated with the success of research and development programs, clinical trial programs including possible delays in patient recruitment, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and additional risk factors discussed in other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. Addit
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
2. Resverlogix is Presenting at IAS HDL Workshop
3. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
4. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
5. Resverlogix Share Option Extension
6. Resverlogix Notice of Conference Call & Webcast
7. /C O R R E C T I O N from Source -- Resverlogix Corp./
8. Industry Leaders Select Resverlogixs RVX-208
9. Resverlogixs Lead Drug Featured in Key Scientific Publication
10. Jan Gray Joins Resverlogix Board of Directors
11. Resverlogix Notice of Conference Call & Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Food and natural product manufacturers, ... food alternatives that offer variety, as well as, ... market has numerous players operating in the marketplace ... Technology (VFT). VFT is a science-driven functional ... all tested to produce stable, effective and repeatable ...
(Date:7/31/2014)... (1912-1954), is famous for a number of breakthroughs, which ... he published a paper, which laid the foundation of ... computer algorithm. He next played a pivotal role in ... the German military codes, enabling the Allies to defeat ... late 1940,s he turned his attention to artificial intelligence ...
(Date:7/31/2014)... New York , July 31, 2014 ... by Transparency Market Research "Quantum Dots Market - Global ... - 2023," the market was valued at USD 88.5 ... 8,246.8 million by 2023, growing at a CAGR of ... full Quantum Dots Market Report at  http://www.transparencymarketresearch.com/quantum-dots.html ...
(Date:7/31/2014)... July 31, 2014 Research and Markets ... Genomics Market 2014-2018" report to their offering. ... is the study of the genetic material or genomes ... strong basis for the discovery and development of diagnostic ... or health conditions. Genomics is supported by three major ...
Breaking Biology Technology:Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... Boston College has been awarded a $1 million grant ... of university researchers developing a new microscope that uses ... and macroscopic matter with significantly improved clarity. The ... new class of microscopes known as "superlenses," which function ...
... 3, 2011 Ron Van Beek, president and CEO ... Synacore Digestive Support for dogs and cats, available exclusively ... synbiotic digestive support supplement containing both probiotics and prebiotics ... microflora in a dog,s or cat,s GI tract.  Van ...
... 3, 2011 Genomic Health, Inc. (Nasdaq: ... successfully surveyed expression of the whole human transcriptome ... Inc., to test hypotheses for biomarker discovery in ... study identified hundreds of coding and non-coding transcripts ...
Cached Biology Technology:Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope 2Van Beek Natural Science Announces New Synacore Digestive Support Product 2Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue 2Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue 3Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue 4
(Date:7/31/2014)... who studied 100 twin pairs have identified a gene mutation ... than six hours of sleep per night. The genetic ... of sleep deprivation. , Results show that a participant with ... an average nightly sleep duration of only five hours, which ... who slept for about six hours and five minutes per ...
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
(Date:7/31/2014)... alters how the brain processes speech, potentially increasing ... neuroscientists at The University of Texas at Dallas. ... Ear and Hearing , researchers demonstrated for ... the brain,s recognition of speech sounds. , Noise-induced ... population, affecting an estimated 15 percent of Americans ...
Breaking Biology News(10 mins):Study of twins discovers gene mutation linked to short sleep duration 2UT Dallas study reveals effect of loud noises on brain 2
... Our brains, it turns out, are eco-friendly. A study published ... Venkatesh Murthy and Jakob Sorensen reveals that our brains have ... cells generate and propagate nerve impulses, or action potentials, by ... and out of the cells. Re-establishing the ion equilibrium after ...
... MADISON, WI, OCTOBER 12, 2009 Areas of ... and recreational (not grazing) purposes, i.e. "urban grasslands" are ... are over 150,000 km2of urban grasslands in the U.S. ... about nutrient runoff to streams, lakes, and estuaries and ...
... 13 CareFusion Corporation (NYSE: CFN ), a new ... the EnVe(TM) ventilator - a high-performance critical care ventilator for ... ventilator is 70-80 pounds lighter than other intensive care ventilators ... help hospitals increase the quality of patient care and decrease ...
Cached Biology News:Nitrogen mysteries in urban grasslands 2Nitrogen mysteries in urban grasslands 3CareFusion Launches EnVe(TM) Ventilator: 10-Pound High-Performance Critical Care Ventilator 2CareFusion Launches EnVe(TM) Ventilator: 10-Pound High-Performance Critical Care Ventilator 3
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
Agarose, Biotechnology grade, 500g...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... c-Jun proto-oncogene was first identified as the cellular ... Jun B and Jun D have been shown ... C-terminal regions, which are involved in dimerization and ... involved in transcriptional activation, diverge. ...
Biology Products: